We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: BellRing Brands, Inc. manufactures and sells nutrition products. The company offers protein shakes, other RTD beverages, powders and nutrition bars and supplements. It offers products under the Premier Protein, Dymatize and PowerBar, as well as Joint Juice and Supreme Protein brands. BellRing Brands, Inc. is based in St. Louis, Missouri.
- Recent BRBR Stock Price: $23.24
- Yearly Gain for BRBR stock: -9.73%
- Market Cap for BRBR stock: $3.06B
- P/E Ratio for BRBR stock: 29.629
Will BRBR's stock price go up? Is there an accurate BRBR stock forecast available?
TipRanks.com reports that BellRing Brands currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $31.13. The target pricing ranges from a high BRBR forecast of $38.00 down to a low forecast of $25.00. BellRing Brands (BRBR)’s last closing stock price was $23.24 which would put the average price target at 33.95% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BRBR stock.
Other analysts covering BRBR include:
- Bill Chappell of Truist Financial issued a Hold rating with the price target of $ 25 on 22 hours ago
- John Baumgartner of Mizuho Securities issued a Buy rating with the price target of $ 38 on 22 hours ago
- Jason English of Goldman Sachs issued a Buy rating with the price target of $ 36 on 22 hours ago
- Pamela Kaufman of Morgan Stanley issued a Buy rating with the price target of $ 28 on 1 month ago
If you are wondering if BRBR is a good stock to buy, here are 3rd party ratings for BRBR stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 49% (128 out of 252)
What is the sentiment on the street regarding BellRing Brands? (Current ratings compiled by TipRanks.com)
- News Sentiment for BRBR stock: Neutral
- Blogger Consensus for BRBR stock: Bullish
- Media Buzz for BRBR stock: Very Low
- Insider Signal for BRBR stock: n/a
- Investor Sentiment for BRBR stock: Very Negative
- Hedge Fund signal for BRBR stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on BRBR stock including scouring the social networks like BRBR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BRBR stock chart >>
Summary: Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France.
- Recent AVDL Stock Price: $8.22
- Yearly Gain for AVDL stock: -17.98%
- Market Cap for AVDL stock: $477.99M
- P/E Ratio for AVDL stock: -3.591
Will AVDL's stock price go up? Is there an accurate AVDL stock forecast available?
TipRanks.com reports that Avadel Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $13.40. The target pricing ranges from a high AVDL forecast of $19.00 down to a low forecast of $9.00. Avadel Pharmaceuticals (AVDL)’s last closing stock price was $8.22 which would put the average price target at 63.02% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AVDL stock.
Other analysts covering AVDL include:
- Oren Livnat of H.C. Wainwright issued a Buy rating with the price target of $ 13 on 22 hours ago
- Francois Brisebois of Oppenheimer issued a Buy rating with the price target of $ 19 on 22 hours ago
- Adam Evertts PhD of LifeSci Capital issued a Buy rating with the price target of $ 14 on 6 days ago
- Marc Goodman of SVB Securities issued a Buy rating with the price target of $ 12 on 1 week ago
If you are wondering if AVDL is a good stock to buy, here are 3rd party ratings for AVDL stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 33% (83 out of 252)
What is the sentiment on the street regarding Avadel Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for AVDL stock: Very Bullish
- Blogger Consensus for AVDL stock: Bullish
- Media Buzz for AVDL stock: Medium
- Insider Signal for AVDL stock: n/a
- Investor Sentiment for AVDL stock: Neutral
- Hedge Fund signal for AVDL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AVDL stock including scouring the social networks like AVDL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AVDL stock chart >>
Summary: Imago BioSciences Inc. is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc. is based in SOUTH SAN FRANCISCO, Calif.
- Recent IMGO Stock Price: $35.59
- Yearly Gain for IMGO stock: -25.42%
- Market Cap for IMGO stock: $588.51M
- P/E Ratio for IMGO stock: -9.505
Will IMGO's stock price go up? Is there an accurate IMGO stock forecast available?
TipRanks.com reports that Imago BioSciences currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $35.75. The target pricing ranges from a high IMGO forecast of $36.00 down to a low forecast of $35.00. Imago BioSciences (IMGO)’s last closing stock price was $35.59 which would put the average price target at 0.45% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMGO stock.
Other analysts covering IMGO include:
- Maury Raycroft of Jefferies issued a Hold rating with the price target of $ 36 on 22 hours ago
- Robert Driscoll of Wedbush issued a Hold rating with the price target of $ 36 on 22 hours ago
- Mitchell Kapoor of H.C. Wainwright issued a Buy rating with the price target of $ 35 on 1 week ago
- Stephen Willey of Stifel Nicolaus issued a Buy rating with the price target of $ 35 on 6 months ago
If you are wondering if IMGO is a good stock to buy, here are 3rd party ratings for IMGO stock:
- TipRanks.com: Hold
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 21% (53 out of 252)
What is the sentiment on the street regarding Imago BioSciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for IMGO stock: Very Bullish
- Blogger Consensus for IMGO stock: n/a
- Media Buzz for IMGO stock: Very High
- Insider Signal for IMGO stock: n/a
- Investor Sentiment for IMGO stock: n/a
- Hedge Fund signal for IMGO stock: Neutral
The stock market is extremely volatile, and you need to do your own research on IMGO stock including scouring the social networks like IMGO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IMGO stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================